Best Peptides for Fat Loss 2026: Ranked by Clinical Data

Tirzepatide targets both GLP-1 and GIP receptors, making it a meaningful step up from single-agonist Semaglutide. The SURMOUNT-1 Phase 3 trial demonstrated 22.5% mean body weight reduction at the highest dose (15mg/week) over 72 weeks. GIP receptor activation amplifies the GLP-1 signal and improves adipocyte insulin sensitivity in ways pure GLP-1 agonism cannot achieve alone.

Tirzepatide closes most of the gap with Retatrutide and remains a strong second-ranked option for fat loss research — particularly where triple agonist protocols are considered too aggressive for initial dose escalation.

Semaglutide was the first GLP-1 agonist to demonstrate clinically meaningful weight loss in the 15% range (STEP-1, 2021). It remains the most extensively studied peptide in this class, with the largest safety dataset. For research protocols emphasizing a well-characterized compound, Semaglutide is the reference standard.

However, when ranked purely on fat loss efficacy, Semaglutide trails both Tirzepatide and Retatrutide by a significant margin — a consequence of operating on a single receptor pathway rather than a synergistic multi-agonist approach.

CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) are not direct fat loss agents — their ranking here reflects their critical supporting role in a cutting protocol. By amplifying natural growth hormone pulses without suppressing endogenous GH production, this combination helps preserve lean muscle mass during aggressive fat loss phases.

When combined with GLP-class agonists, CJC-1295/Ipamorelin can meaningfully shift the ratio of fat loss to lean mass retention — the defining variable for body recomposition rather than simple weight loss. Pre-sleep administration aligns with the body's natural nocturnal GH pulse for maximum effect.

BPC-157 does not directly drive fat loss, but it earns a place in every serious fat loss research protocol for one key reason: GLP receptor agonists frequently cause gastrointestinal side effects (nausea, gastric discomfort, slowed motility) that disrupt protocol adherence.

BPC-157 is a 15-amino-acid gastric protection peptide that upregulates VEGF for mucosal repair and activates nitric oxide pathways. In animal research it has demonstrated accelerated healing of gut tissue and reduction of GI inflammation. Running BPC-157 alongside Retatrutide forms the basis of the Clavicular recomp stack — managing the most common limiting factor in GLP-class research protocols.